Podcast appearances and mentions of Jefferson Health

On today's episode of What's Going On, we spotlight community giving and innovative approaches to better health, featuring two powerful conversations making a real difference in Philadelphia. Rodney McLeod & Change Our Future Holiday GiveawayWe begin with former Philadelphia Eagle and Super Bowl champion Rodney McLeod and his wife Erika, who continue their commitment to service through their nonprofit, Change Our Future. This holiday season, they are expanding their impact by adopting 10 families and providing 250 Philadelphia children with winter coats, hats, gloves, scarves, toys, and food. Rodney shares the inspiration behind the organization and details their upcoming holiday giveaway designed to support families during the coldest months of the year.Event Details

Life after welcoming a baby into the world looks different – it's messy, beautiful and exhausting. As you nurture the newest addition to your family, remember yourself too. Hormones shift significantly after giving birth, which can leave you feeling sad, anxious or overwhelmed.  If you're looking for support in postpartum, you'll want to listen to the latest episode of The Healthiest You podcast about postpartum depression. In Part Two of our podcast series, you'll hear from psychiatrist Samantha Cerimele, MD, with Lehigh Valley Health Network, part of Jefferson Health. Is it “baby blues” or postpartum depression? What increases your risk for postpartum depression? Should you try placenta encapsulation? What treatment options are available for postpartum depression? How can the WAVES (Women Adjusting to Various Emotional States) program help? We answer these questions and more on The Healthiest You podcast this month. Chapters:0:01 - Intro0:11 - “Baby blues” vs. postpartum depression1:27 - This may increase your risk for postpartum depression2:15 - Ways to prevent postpartum depression3:09 - Placenta encapsulation5:17 - Reaching out for help6:04 - Treatment options 8:57 - Talk therapy10:01 - Helpful things to include in your routine11:45 - Advice for moms and our programs

In this episode, Dr. Joseph Cacchione, Chief Executive Officer of Jefferson Health, and Alex Pinto, Principal at ECG Management Consultants, discuss how health systems can enhance patient access through standardized scheduling, technology integration, and strong physician engagement while navigating cultural and generational shifts in healthcare delivery.

This episode recorded live at the 10th Annual Health IT + Digital Health + RCM Annual Meeting features Luis Taveras, SVP and Chief Information Officer at Jefferson Health. He discusses the rapid impact of ambient AI, how to scale digital tools without overwhelming operations, and why leaders should focus on value as technology and care demands continue to accelerate.

On average, you have over 6,000 thoughts a day. That's a lot – and about 80 percent of them are negative. Unsettling thoughts, lingering feelings of sadness or losing interest in activities you once enjoyed are all reasons to check in on your mental health with a trusted friend or your clinician.  If you're looking for options because something feels off or you know a loved one who is facing depression, you'll want to listen to the latest episode of The Healthiest You podcast. In Part One of our podcast series on major depression, you'll hear from psychiatrist Samantha Cerimele, MD, with Lehigh Valley Health Network, part of Jefferson Health. How can you break the cycle of negative thoughts? What causes depression? Which symptoms should not be ignored? Should you try transcranial magnetic stimulation (TMS) therapy? Can St. John's wort supplements help fight depression? We answer these questions and more on The Healthiest You podcast this month.Chapters:0:01 - Intro1:06 - Why women have a higher risk2:16 - What causes depression2:31 - Most common types of depression3:04 - Symptoms you should not ignore 4:33 - Take these first steps if you have symptoms5:35 - How depression is diagnosed6:16 - Treatment options7:15 - Nonmedication treatment options7:33 - Transcranial magnetic stimulation (TMS)8:49 - Side effects of TMS9:14 - Cognitive behavioral therapy (CBT) or talk therapy10:19 - Mental health toolkit11:39 - What to do when your thoughts are spiraling12:16 - Breathing exercise14:29 - St. John's wort supplement

October Breast Cancer Awareness Month may be behind us, but the fight against breast cancer continues every day. With 1 in 8 women in the U.S. expected to develop invasive breast cancer in their lifetime, early detection remains one of the most powerful tools we have — reducing the risk of death by more than 30%. Joining us is Jennifer Pantleo, Certified Breast Care Nurse and Vice President of Clinical Programs at Solis Mammography, a national leader in breast health services for nearly 40 years. Jennifer shares how Solis Mammography's partnership with Jefferson Health is expanding access across the Philadelphia region, how AI-enhanced 3D imaging is improving early detection, and why staying on top of annual screenings can be lifesaving. We'll also highlight the new Jefferson Health–Solis center in Flourtown and how listeners can schedule their appointments.  

Leaking after sneezing or exercising, rushing to the restroom and experiencing pelvic discomfort are health problems often tucked away on a to-do list of things to deal with later. These everyday disruptions though are signs that your pelvic floor needs some attention. Whether you've recently had a baby or you're approaching your menopause era, there are treatment options that can fit into your routine and help you feel better.  If you're looking for ways to support your bladder naturally or wondering how pelvic floor physical therapy could benefit you, you'll want to listen to the latest episode of The Healthiest You podcast. In Part Two of our pelvic floor podcast series, you'll hear from urogynecologist Nabila Noor, MD, and rehabilitation clinical specialist Karen Snowden, PT, DPT, both with Lehigh Valley Health Network, part of Jefferson Health.Which supplements may support your bladder health? What is pelvic organ prolapse? What treatment options are available for pelvic floor disorders? How can you strengthen your pelvic floor at home? What can you expect at your first pelvic floor physical therapy appointment? We answer these questions and more on The Healthiest You podcast this month.Chapters:     • 0:01 - Intro     • 0:04 - Toilet stools     • 3:52 - Bladder supplements     • 7:16 - Pelvic organ prolapse     • 9:11 - Treatment options     • 12:11 - Pelvic floor physical therapy     • 20:42 - Exercises at your appointment     • 26:20 - How to strengthen your pelvic floor at home     • 35:18 - Advice for your bladder and pelvic floor

Your pelvic floor is ready and waiting for you to break up with these habits:Power-peeing – Going to the bathroom is not a race. Forcing urine out or relieving yourself as fast as you can causes more harm than good to your pelvic floor. Hovering – This seems like a natural solution to avoid germs in public restrooms. But hovering over the toilet tenses your muscles which makes your bladder work harder than it needs to.Peeing “just in case” – Went 15 minutes ago? Maybe going once more is a good idea … or is it? Whether you're heading out for an errand or a road trip, going again “just in case” is training your bladder to go more frequently.  If you're ready to take back control of your bladder, you'll want to listen to the latest episode of The Healthiest You podcast. In Part One of our pelvic floor podcast series, you'll hear from urogynecologist Nabila Noor, MD, and rehabilitation clinical specialist Karen Snowden, PT, DPT, with Lehigh Valley Health Network, part of Jefferson Health. How do you know if you have a pelvic floor disorder? What bathroom habits are harming your pelvic floor? How many times a day should you urinate? Can bladder training help? Which exercises can strengthen your pelvic floor? We answer these questions and more on The Healthiest You podcast this month.Chapters:     · 0:01 - Intro     · 0:17 - About your pelvic floor     · 3:31 - When your pelvic floor changes     · 6:49 - Signs you may have a pelvic floor disorder      · 15:54 - Treatment options     · 17:45 - Bladder leaks and overactive bladder      · 20:26 - How to address overactive bladder     · 23:56 - When to stop drinking before bed     · 29:06 - Bathroom no-nos     · 34:07 - Bladder training

Robin Shine Maddox, Founder and Visionary behind She Shines discussed the 6th annual conference, November 1st a New Covenant Church in Germantown; how it and her Celebrating Sisterhood campaign were inspired by her breast cancer journey and her desire to gather women to network, educate and inspire each other. The pillars of the free conference are Civic Engagement/Voting Rights, Health/Wellness/Safety and Spiritual Enrichment. Open to all women of all walks of life and women of color, there will be Black and brown vendors - most of them women - in a Marketplace, workshops with networking and information for women entrepreneurs, healthcare and mental health screenings, the Jefferson Health mobile screening unit for mammograms, and discussions by featured panelists and guests. For more information and wait-list registration go to sheshinesconference.com. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode recorded live at the 10th Annual Health IT + Digital Health + RCM Annual Meeting features Judd Hollander, here he discusses how Jefferson Health is using AI tools like ambient listening to reduce administrative burdens and combat clinician burnout. He also shares insights on governance, long-term innovation strategy, and balancing technology adoption with operational needs.

The revenue cycle helps keep hospital revenue flowing. But sometimes, it seems to sputter out, as if not all the cylinders are firing. And that is why the producers of Talk Ten Tuesdays have invited longtime ICD10monitor editorial consultant Dennis Jones, senior director of revenue cycle at the famed Jefferson Health, to be the special guest during the next live edition of the weekly Internet radio broadcast.The popular broadcast will also feature these instantly recognizable panelists, who will report more news during their segments:• CDI Report: Cheryl Ericson, Senior Director of Clinical Policy and Education for the vaunted Brundage Group, will have the latest clinical documentation integrity (CDI) updates.• Social Determinants of Health: Tiffany Ferguson, CEO for Phoenix Medical Management, Inc., will report on the news that is happening at the intersection of medical record auditing and the SDoH.• The Coding Report: Christine Geiger, Assistant Vice President of Acute and Post-Acute Coding Services for First Class Solutions, will report on the latest coding news.• News Desk: Timothy Powell, ICD10monitor national correspondent, will anchor the Talk Ten Tuesdays News Desk.

In this episode, Dr. Joseph G. Cacchione, CEO of Jefferson Health, shares how lessons from coaching, clinical practice, and personal experiences have shaped his leadership philosophy. He discusses the emotional core of healthcare, the importance of humility, and how strong relationships and frontline support are key to resilient organizations.

Send us a textDr. Karen Knudsen, MBA, PhD, is the Chief Executive Officer of The Parker Institute for Cancer Immunotherapy ( PICI - https://www.parkerici.org/ ), a 501c3 nonprofit organization driving the next generation of cancer treatment by accelerating the development of breakthrough immune therapies to turn all cancers into curable diseases.Dr. Knudsen most recently served as the Chief Executive Officer of the American Cancer Society (ACS) and ACS Cancer Action Network (ACS CAN), where she led both organizations through a period of transformative growth, significantly expanding research investments, advocacy reach, and direct patient support initiatives. Under her leadership, ACS evolved into a unified, high-performing enterprise, increasing revenue by more than 30 percent and broadening its impact to serve over 55 million lives annually. Moreover, Dr. Knudsen developed and scaled innovative programs that included joint ventures and an impact innovation arm to accelerate progress against cancer.Prior to ACS, Dr. Knudsen served as Executive Vice President of Oncology Services at Jefferson Health and Enterprise Director of the Sidney Kimmel Comprehensive Cancer Center, growing a multi-state oncology network and spearheading advancements in translational cancer research that increased early access to the most advanced cancer care. A globally recognized expert in prostate cancer, Dr. Knudsen has authored over 200 scientific publications and generated practice-changing discoveries. Dr. Knudsen held leadership roles with organizations including the National Cancer Institute Board of Scientific Advisors, the Association of American Cancer Institutes, and the American Association for Cancer Research. She currently serves on the boards of Exai Bio, Paradigm Health, and Research!America, and advises multiple biotech ventures including ArteraAI and Transcarent.Dr. Knudsen holds numerous awards for her scientific and healthcare accomplishments, and this year will be honored with the Allen Lichter Visionary Leader Award from the American Society of Clinical Oncology (ASCO), recognizing her lifetime achievement of outstanding contributions to the field of oncology.Dr. Knudsen holds a PhD in Biological Sciences from the University of California, San Diego, and an MBA from Temple University's Fox School of Business. She has been recognized as one of Forbes' “50 Over 50: Women of Impact”, a CNBC Changemaker, and is a CEO Council Member for both the Wall Street Journal and CNBC.#Oncology #Immunooncology #Cancer #KarenKnudsen #ParkerInstituteForCancerImmunotherapy #AmericanCancerSociety #JeffersonHealth #UniversityOfCalifornia #LudwigInstituteForCancerResearch #UniversityOfCincinnati #ProstateCancer #CART #CellTherapy #CheckpointInhibitors #TumorAntigenDiscovery #TumorMicroenvironment #OncolyticViruses #Pluvicto #Philadelphia #CarlJune #JamesAllison #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Does menopause ever end? When you're on your third cup of coffee because of another sleepless night and dealing with your fifth hot flash of the day, you can't help but wonder. The answer to that question may surprise you.  If you are in your menopause era, you'll want to listen to the latest episode of The Healthiest You podcast, where we talk about how to navigate each stage of menopause with OB-GYN and Menopause Society Certified Practitioner Susan Haas, MD, PhD, with Lehigh Valley Health Network, part of Jefferson Health.  What can you do about meno belly? How can you get better sleep? What can you do about hair shedding or hair loss? Which diet and exercises are best for menopausal women? Does menopause ever end? We answer these questions and more on The Healthiest You podcast this month. Want more on the stages of menopause? Check out part one of our menopause podcast miniseries.  Chapters:     · 0:01 - Intro     · 0:06 - Positives to menopause     · 2:43 - Health screenings     · 5:11 - Sleep disruptions     · 8:38 - Finding emotional balance     · 11:48 - Sexual health      · 21:30 - Hair shedding     · 26:06 - How to know if you're in menopause      · 30:07 - Meno belly     · 33:35 - Recommended exercise      · 34:27 - Nutrition     · 38:05 - Soothing dry skin     · 39:36 - Caffeine and hot flashes      · 40:25 - Joint and muscle pain relief     · 42:47 - Frozen shoulder and menopause     · 43:38 - Surprising symptoms     · 46:54 - Migraines     · 48:17 - Does menopause ever end?

Why is palliative care so important in ILD, especially in early diagnosis? How would you define palliative care, especially in the context of ILD? Dr. Gillian Love of the Division of Palliative Care with Jefferson Health joins Crockett to discuss these questions and more in the 'Pulmonary Fibrosis' podcast! Brought to you by the Wescoe Foundation for Pulmonary Fibrosis -- and the PAIPF Support Network -- visit PAIPFsupportnetwork.org!See omnystudio.com/listener for privacy information.

Like the life cycle of a butterfly, menopause is a transformative season that has its highs and lows. Saying goodbye to periods and embracing the beauty found in midlife are the positives. But dealing with frustrating symptoms like hot flashes, insomnia, mood changes and more can feel overwhelming.  If you are in your menopause era, you'll want to listen to part one of the latest episode of The Healthiest You podcast, where we talk about how to navigate each stage of menopause with OB-GYN and Menopause Society Certified Practitioner Susan Haas, MD, PhD, with Lehigh Valley Health Network (LVHN), part of Jefferson Health.  What age does menopause start? How long does menopause last? What can help with hot flashes? Can all women take menopausal hormone therapy? How is bone health impacted during menopause? We answer these questions and more on The Healthiest You podcast this month. Chapters:     · 0:01 - Intro     · 1:08 - Perimenopause and menopause     · 4:40 - Menstrual cycle changes     · 8:23 - Help with hot flashes     · 12:27 - Hormone therapy     · 13:16 - When to consider hormone therapy     · 14:51 - Alternative treatment options     · 22:23 - Risks of hormone therapy     · 25:36 - If you've had a total hysterectomy      · 29:22 - Bone health and calcium supplements      · 33:19 - Estrogen and progesterone      · 36:47 - Urinary tract infections (UTIs)     · 38:55 - Part two coming soon

It's a busy week on 94WIP as the Morning and Midday Shows are back at Eagles Champ Camp interviewing Jahan Dotson, Will Shipley, Azeez Ojulari and Josh Uche among others. Plus, Scott Franzke and Larry Andersen call in to discuss a tough week for the Phillies and Dr. Arjun Ramprasad of Jefferson Health calls the Morning Show to break down Landon Dickerson's meniscus injury.

It's a busy week on 94WIP as the Morning and Midday Shows are back at Eagles Champ Camp interviewing Jahan Dotson, Will Shipley, Azeez Ojulari and Josh Uche among others. Plus, Scott Franzke and Larry Andersen call in to discuss a tough week for the Phillies and Dr. Arjun Ramprasad of Jefferson Health calls the Morning Show to break down Landon Dickerson's meniscus injury.

It's a busy week on 94WIP as the Morning and Midday Shows are back at Eagles Champ Camp interviewing Jahan Dotson, Will Shipley, Azeez Ojulari and Josh Uche among others. Plus, Scott Franzke and Larry Andersen call in to discuss a tough week for the Phillies and Dr. Arjun Ramprasad of Jefferson Health calls the Morning Show to break down Landon Dickerson's meniscus injury.

In this episode, Dr. Joseph G. Cacchione, CEO of Jefferson Health, shares how lessons from coaching, clinical practice, and personal experiences have shaped his leadership philosophy. He discusses the emotional core of healthcare, the importance of humility, and how strong relationships and frontline support are key to resilient organizations.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management" Alex Dessy, MD, clinical assistant professor in movement disorders at Jefferson Health, shares a comprehensive look at modern-day care strategies for patients with Parkinson disease and other movement disorders. Dessy discusses the foundational role of detailed history-taking, exam-based observation, and phenomenology in diagnosing complex conditions, along with the growing utility of genetic and imaging tools. She also explains the challenges of managing nonmotor symptoms—like sleep disturbance, fatigue, and constipation—and how lifestyle strategies and interdisciplinary collaboration are often as vital as medication. Lastly, she emphasizes the importance of clear and compassionate communication with patients and families as neurology becomes increasingly therapeutic. Looking for more Movement disorders discussion? Check out the NeurologyLive® Movement disorders clinical focus page. Episode Breakdown: 1:00 – How movement disorder diagnosis is approached through history, physical exam, and phenomenology 4:05 – What makes certain movement disorder cases complex and how diagnostics like genetics and imaging are used 6:20 – Neurology News Minute 8:45 – How nonmotor symptoms in Parkinson's (fatigue, constipation, sleep) are managed with lifestyle strategies 12:30 – Approaching therapeutic communication and expectation-setting with patients and families The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Eisai Showcases Promising 4-Year Data for Alzheimer Therapy Lecanemab at AAIC 2025 IHL-42X to Enter Phase 3 Trials for Obstructive Sleep Apnea Following Positive Phase 2 Data FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

 The mere mention of the phrase artificial intelligence can elicit a wide variety of emotions, be they the joy of potential innovation, uncertainty about future impacts and everything in between. Still, it is impossible to deny that AI is already embedding itself in our collective lives in ways both big and small, which is why the enterprise has set out to embrace its positives, and keep up with the emerging technological advances. This episode of the Thomas Jefferson University News Podcast takes a deeper look at the variety of ways in which artificial intelligence is being incorporated into academic programs, the health system, and Jefferson Health plans. It is truly a one Jefferson effort to harness the benefits of emerging technology and weigh potential pitfalls to better position the enterprise for the future. SOCIAL CHANNELS: Facebook: https://www.facebook.com/JeffersonUniv/ Twitter: https://twitter.com/JeffersonUniv Instagram: https://www.instagram.com/jeffersonuniv/?hl=en TikTok: @_jeffersonuniv_ YouTube: https://www.youtube.com/c/JeffersonUniv LinkedIn: https://www.linkedin.com/school/thomas-jefferson-university

It's a Medicaid Madness mess.For many years, Medicaid has been providing support for America's most vulnerable populations. But now, Medicaid finds itself as a pawn, being manipulated for political gain between two opposing forces: those who view the program as a means to an end to reduce government spending, and those who hold the opposite point of view.Who will be the winners and losers? During the next live edition of the venerated Monitor Mondays, senior healthcare consultant Dennis Jones will report on how hospitals can save money in the face of the inevitable Medicaid cuts.Jones, senior director of revenue cycle at Jefferson Health, was among the first of hand-picked subject-matter experts heard nearly 14 years ago on the weekly Internet broadcast produced by RACmonitor.The Monday's broadcast will also include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Risky Business: Sitting in for healthcare attorney David Glaser will be attorney Marguarite Ahman, a shareholder in the law offices of Fredrikson & Byron.• Legislative Update: Matthew Albright, chief legislative affairs analyst for Zelis, will report on the news happening at the intersection of healthcare and congressional action.

Artificial intelligence (AI) has quickly transitioned from something to expect in the future to the here and now today. The potential for AI in health information is both exciting and daunting. Reporting the lead story during the next live edition of Talk Ten Tuesday will be longtime RACmonitor and ICD10monitor contributing author Sharon Easterling.Sharon Easterling is slated to create an editorial series on artificial intelligence. Her report on this topic will be a preview of what readers and listeners will learn during her series.The popular Internet broadcast will also feature these additional instantly recognizable panelists, who will report more news during their segments:• Social Determinants of Health: Tiffany Ferguson, CEO for Phoenix Medical Management, Inc., will report on the news that is happening at the intersection of medical record auditing and the SDoH;• The Coding Report: Christine Geiger, Assistant Vice President of Acute and Post-Acute Coding Services for First Class Solutions, will report on the latest coding news;• Field Report: Dennis Jones, a veteran Monitor Mondays and Talk Ten Tuesdays contributing author, will report on the latest developments regarding the revenue cycle. Jones is the senior director of revenue cycle at Jefferson Health.• News Desk: Timothy Powell, ICD10monitor national correspondent, will anchor the Talk Ten Tuesdays News Desk; and• MyTalk: Angela Comfort, veteran healthcare subject-matter expert, will co-host the long-running and popular weekly Internet broadcast. Comfort is the Assistant Vice President of Revenue Integrity for Montefiore Health.

Stories around substance use disorder (SUD) have too often been framed around crisis and moral failing. But SUD is a health condition—no different from heart disease or cancer—and it deserves public response rooted in care, not stigma. San Francisco is working to change that narrative. Through evidence-based treatment, innovative telehealth programs, and groundbreaking stigma-reduction campaigns like Living Proof, the city is reimagining recovery and how public health can meet people where they are. Dr. Jeffrey Hom, Medical Officer for Science and Policy in San Francisco's Department of Public Health Substance Use Services joins us to discuss how storytelling can shift public perception, and accessible services can guide people onto paths of recovery. The conversation is a reminder that recovery becomes possible when health systems lead with both science and empathy. Dr. Jeffrey Hom is the San Francisco Department of Public Health's Substance Use Services Medical Officer for Science and Policy. He previously served as medical director for the City of Philadelphia's Division of Substance Use Prevention and Harm Reduction and has lectured for Jefferson Health and the University of Pennsylvania. More Links and Information  Check out more Fors Marsh Media  Connect or partner with Fors MarshLearn more about San Francisco's Night Navigator and street care programs Hear from people recovering from SUD in San Francisco through Living Proof   

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Could physician advisors become dinosaurs in healthcare, bound for extinction?The role of the physician advisor has developed into an absolute necessity in hospitals of all sizes around the country. As the healthcare landscape rapidly evolves, physician advisors have served as critical players, bridging the gap between confusion and clarity within clinical and administrative functions.Yet, the question remains unanswered: why are only a fraction of physician advisors employed as full-time employees?During the next live edition of Talk Ten Tuesdays, Juliet B. Ugarte Hopkins, MD, Medical Director of Phoenix Medical Management, Inc., will report on the pitfalls of inadvertently diluting the physician advisor's focus and level of expertise.The popular Internet broadcast will feature the additional following instantly recognizable panelists, who will report more news during their segments:• CDI Report: Cheryl Ericson, Director of clinical documentation integrity (CDI) for the vaunted Brundage Group, will have the latest CDI updates;• The Coding Report: Christine Geiger, Assistant Vice President of Acute and Post-Acute Coding Services for First Class Solutions, will report on the latest coding news;• Field Report: Dennis Jones, a veteran Monitor Mondays and Talk Ten Tuesdays contributing editor, will report on the latest developments regarding the revenue cycle. Jones is the senior director of revenue cycle at Jefferson Health;• News Desk: Timothy Powell, ICD10monitor national correspondent, will anchor the Talk Ten Tuesdays News Desk; and• Point of View: Dr. Kennedy will report on his efforts to advocate for a change in the definition of sepsis. Dr. Kennedy will be sitting in for Angela Comfort, who continues as the co-host for the long-running and popular weekly Internet broadcast.

One of the largest regional coding organizations in America's healthcare universe – the California Health Information Association (CHIA) – wrapped its final workshops this past week, with delegates flying home to share their insights on what was considered to be a pivotal experience.The ICD10monitor producers of Talk Ten Tuesdays have secured a rare appearance of CHIA's past president, Gloryanne Byrant, who agreed to share five key takeaways from the annual conference.During the next live edition of Talk Ten Tuesdays, coming up at 10 a.m. EST on June 10, the popular Internet broadcast will feature the additional following instantly recognizable panelists, who will report more news during their segments:• CDI Report: Cheryl Ericson, Director of CDI for the vaunted Brundage Group, will have the latest CDI updates;• Field Report: Dennis Jones, a veteran Monitor Mondays and Talk Ten Tuesdays contributing editor, will report on the latest developments regarding the revenue cycle. Jones is the administrator of the revenue cycle at Jefferson Health;The Coding Report: Christine Geiger, Assistant Vice President of Acute and Post-Acute Coding Services for First Class Solutions, will report on the latest coding news;• News Desk: Timothy Powell, ICD10monitor national correspondent, will anchor the Talk Ten Tuesdays News Desk; and• MyTalk: Angela Comfort, veteran healthcare subject-matter expert, will co-host the long-running and popular weekly Internet broadcast. Comfort is the Assistant Vice President of Revenue Integrity for Montefiore Health.

It's no surprise that the Mediterranean diet was ranked as the best overall diet by U.S. News & World Report for the eighth year in a row. This style of eating focuses more on fueling your body with the right foods and enjoying healthy meals with others rather than following a restrictive plan.  Listen to the latest episode of The Healthiest You podcast, where we talk about the Mediterranean diet with dietitian Alexa Roseberry with Lehigh Valley Health Network (LVHN), part of Jefferson Health.  Can following the Mediterranean diet make you live longer? What if you don't like fish and you aren't a fan of vegetables? How can you make healthier choices going out to eat? Which one is better – the Mediterranean diet or the DASH (Dietary Approaches to Stop Hypertension) diet? Are there ways to stop the post-lunch slump? We answer these questions and more on The Healthiest You podcast this month.Chapters:     · 0:01 - Intro     · 1:13 - About the Mediterranean diet     · 3:54 - Mediterranean diet pyramid     · 6:41 - Meals with others     · 10:05 - If you don't like fish or vegetables     · 12:01 - Healthy fats     · 17:14 - Meal ideas     · 18:49 - Snack ideas     · 21:12 - Dessert ideas     · 24:41 - Budget and meal planning tips     · 30:48 - Live longer on the Mediterranean diet     · 34:54 - Daily fiber intake     · 35:32 - Mediterranean diet and PCOS     · 36:42 - DASH diet vs. Mediterranean diet     · 38:52 - High-protein, low-carb diet     · 41:26 - Nutrition tips if you've had a colectomy and have an ileostomy      · 44:03 - Gaining strength back after surgery     · 47:45 - Signs you're not eating enough protein     · 49:44 - How to make healthier choices at restaurants      · 52:38 - Stop the post-lunch slump     · 54:30 - Nutrition advice

Think menopause is why you're gaining weight? It's not. The truth: your metabolism stays stable from age 20 to 60. What does change? Your energy balance—and most women don't see it happening. In this episode, I unpack the real reason weight loss feels harder now, and what you can do to shift it. You'll learn how energy in (food) vs. energy out (movement) drives fat loss, why tracking intake matters more than ever, and how your body subtly burns less as you lose weight—without you even noticing. What you'll walk away with: Why “calories” are just energy—and why mindset around them matters The law of thermodynamics: no one gets around it How untracked changes in daily movement stall fat loss Why tracking isn't about judgment—it's data to guide your goals What's really behind midlife weight gain (and it's not your hormones) Cut through the confusion. If weight loss has felt impossible lately, this might be the missing piece.   Get Weekly Health Tips:  thrivehealthcoachllc.com Let's Connect:@‌ashleythrivehealthcoach or via email: ashley@thrivehealthcoachingllc.com Podcast Produced by Virtually You! Sources: Hall, K. D., Heymsfield, S. B., Kemnitz, J. W., Klein, S., Schoeller, D. A., & Speakman, J. R. (2012). Energy balance and its components: Implications for body weight regulation. The American Journal of Clinical Nutrition, 95(4), 989–994. https://doi.org/10.3945/ajcn.112.036350 Thomas, J. G., Bond, D. S., Raynor, H. A., Papandonatos, G. D., & Wing, R. R. (2017). Comparison of smartphone-based behavioral obesity treatment with gold standard group treatment and control: A randomized trial. Obesity, 25(6), 964–972. Chronic intestinal electrical stimulation improves glucose intolerance and insulin resistance in diet‐induced obesity rats Ducrot, P., Méjean, C., Aroumougame, V., Ibanez, G., Allès, B., Kesse-Guyot, E., ... & Péneau, S. (2017). Meal planning is associated with food variety, diet quality and body weight status in a large sample of French adults. The International Journal of Behavioral Nutrition and Physical Activity, 14(1), 12. Meal planning is associated with food variety, diet quality and body weight status in a large sample of French adults - International Journal of Behavioral Nutrition and Physical Activity Catenacci, V. A., Ogden, L. G., Stuht, J., Phelan, S., Wing, R. R., Hill, J. O., & Wyatt, H. R. (2008). Physical activity patterns in the National Weight Control Registry. Obesity, 16(1), 153–161. Relationship Between Body Mass Index and Gray Matter Volume in 1,428 Healthy Individuals Butryn, M. L., Phelan, S., Hill, J. O., & Wing, R. R. (2007). Consistent self-monitoring of weight: A key component of successful weight loss maintenance. Obesity, 15(12), 3091–3096. Consistent Self‐monitoring of Weight: A Key Component of Successful Weight Loss Maintenance Wing, R. R., & Phelan, S. (2005). Long-term weight loss maintenance. The American Journal of Clinical Nutrition, 82(1), 222S–225S. https://doi.org/10.1093/ajcn/82.1.222S Wing, R. R., Papandonatos, G. D., Fava, J. L., Gorin, A. A., Phelan, S., McCaffery, J., & Tate, D. F. (2008). Maintaining large weight losses: The role of behavioral and psychological factors. Journal of Consulting and Clinical Psychology, 76(6), 1015–1021. APA PsycNet Mayo Clinic. (2021). Menopause weight gain: Stop the middle age spread. Mayo Clinic. The reality of menopause weight gain Jefferson Health. (n.d.). The truth about menopause: Debunking 6 common misconceptions. Jefferson Health. The Truth About Menopause: Debunking 6 Common Misconceptions | Jefferson Health American Heart Association. (n.d.). Food diary – How to keep track of what you eat. AHA Healthy Eating. Food Diary — Keep Track of What You Eat and Drink National Weight Control Registry. (n.d.). NWCR Facts. https://www.nwcr.ws McGrath, E. (2025, May 29). Using this 'inclusion strategy' can help you lose weight — and means you get to eat dessert. New York Post. Using this 'inclusion strategy' can help you lose weight — and...

In this episode, Dr. Luis E. Taveras, SVP & CIO of Jefferson Health, shares how Jefferson is driving enterprise-wide integration, strengthening cybersecurity, and adopting a value-driven AI governance model—all while keeping people at the center of healthcare innovation.

Send us a textAmy Wright is the Director of Urgent Care, Telehealth and Access at Jefferson Health, and a candidate for the Board of Directors of the Urgent Care Association

In this episode, Aaron Chang, FACHE and President of Jefferson Health East Region, joins Laura Dyrda to discuss how Jefferson is expanding access to care, addressing workforce challenges, and investing in clinical innovation. He also shares insights on leadership, partnerships, and the impactful oncology expansion bringing expert cancer care closer to South Jersey communities.

Living with polycystic ovarian syndrome or PCOS can take a toll on your emotional and physical health. Common symptoms of this condition are irregular periods, infertility, weight gain and unwanted hair growth – all of which are difficult to cope with.  Listen to the latest episode of The Healthiest You podcast, where we talk about how to manage PCOS with OB-GYN Emily Brophy, MD, with Lehigh Valley Health Network (LVHN), part of Jefferson Health.   What are the symptoms of PCOS? How does PCOS impact ovulation and fertility? What lifestyle changes may help manage PCOS symptoms? Which supplements may provide hormonal support? What diet changes may help women who have PCOS? We answer these questions and more on The Healthiest You podcast this month.Chapters:     · 0:01 - Intro     · 1:00 - What is PCOS?     · 2:05 - Is PCOS genetic?     · 2:46 - Challenges with diagnosing PCOS     · 3:41 - Irregular periods     · 4:38 - Tracking your cycle     · 5:58 - DUTCH test     · 7:21 - PCOS treatment options     · 8:53 - Sharing your diagnosis with your health care team     · 10:08 - Lifestyle changes to help manage PCOS     · 10:58 - Recommended diet changes     · 11:54 - How to reduce the bloating     · 12:37 - PCOS supplements     · 14:57 - Evening primrose oil     · 15:28 - Inositol and PCOS     · 15:47 - Magnesium supplements     · 17:24 - Chasteberry and black cohosh     · 18:21 - Inflammation and PCOS     · 19:11 - Importance of exercise     · 20:30 - Unwanted hair growth     · 22:11 - Spearmint tea     · 22:43 - Ovulation and fertility     · 23:45 - Tracking ovulation     · 25:16 - Mental health and PCOS     · 26:34 - Acupuncture and acupressure     · 28:04 - If you've had your symptoms dismissed      · 29:57 - Advice

Ryan Patterson (Senior Director, Ambulatory Operations at Jefferson Health) and Sherry Onushco (Director at Lehigh Valley Health Network) discuss exciting changes they're making in their networks to streamline checking in, checking out and payment. This episode is brought to you by our good friends at Switch RCM. Please reach out to Nate and the team: Nate@switchrcm.com You will not regret it. Those cats are doing some very interesting things. Don't forget to like and subscribe!

In this episode, Editor-in-Chief Alan Condon breaks down the latest hospital financial trends, including stable margins and rising service volumes. He also discusses the growing tensions in payer-provider negotiations, highlighted by Jefferson Health's contract dispute with Cigna.

In this episode, Scott Becker breaks down seven key healthcare stories, including Cigna and Jefferson Health's contract split, Mercy Health's financial challenges, and a positive upswing in hospital margins.

In this episode, Scott Becker speaks with Dr. Joseph Cacchione, CEO of Jefferson Health and Thomas Jefferson University. Dr. Cacchione discusses the system's growth, the challenges facing healthcare—including reimbursement cuts and financial headwinds—and the importance of integrating care delivery with financing.

Dr. Baligh Yehia, President of Jefferson Health, joins the Becker's Healthcare Podcast to discuss Jefferson Health's growth strategy, workforce development, and the evolving healthcare landscape. He shares insights on the impact of AI, rising healthcare costs, and the significance of hospital mergers, including Jefferson's integration with Lehigh Valley.

Your thyroid is a small, butterfly-shaped gland in your neck that can have a big impact on your health. It's responsible for making hormones that affect your metabolism, heart rate, mood and more.  Listen to the latest episode of The Healthiest You podcast, where we talk about thyroid issues with Andrew Brackbill, MD, endocrinologist with Lehigh Valley Health Network (LVHN), part of Jefferson Health.   Why are women more prone to having a thyroid issue? What is the difference between hyperthyroidism and hypothyroidism? How does Hashimoto's disease affect your health? How might having a thyroid problem impact fertility? Can thyroid conditions impact your mental health? We answer these questions and more on The Healthiest You podcast this month.Chapters:      · 0:01 - Intro     · 0:56 - The main function of your thyroid     · 2:16 - Why women are more likely to have a thyroid problem     · 6:14 - Fatigue and your thyroid      · 12:18 - Symptoms of a thyroid problem     · 13:17 - Temperature intolerances     · 13:58 - Hypothyroidism vs. hyperthyroidism      · 15:45 - Diagnosing thyroid conditions     · 16:57 - How thyroid disorders impact your life     · 19:49 - Hashimoto's disease and hypothyroidism      · 20:49 - Fertility and thyroid conditions     · 23:18 - Menopause and your thyroid      · 25:01 - Diet and your thyroid     · 28:08 - Weight and your thyroid      · 29:51 - Addressing weight issues     · 31:25 - Stress and your thyroid     · 32:45 - Stress management tips     · 33:35 - Mental health and your thyroid      · 36:06 - Wellness strategies      · 38:03 - Treatment options for thyroid conditions     · 44:12 - Getting a thyroid panel     · 45:20 - What is shown in your thyroid panel     · 47:02 - At-home thyroid tests

In this episode, Scott Becker highlights seven major healthcare stories, including Orlando Health's hospital closure, leadership changes at Penn State and Jefferson Health, workforce challenges leading to a UC healthcare worker strike, and growing cybersecurity concerns in health systems.

When it comes to improving heart health, there are simple, science-backed ways to strengthen your heart right from home, according to Dr. Matthew Delfiner, a cardiologist who specializes in advanced heart failure, transplant cardiology, and pulmonary hypertension at Jefferson Health. In this episode, learn about why being sedentary is so bad for your health, how small changes, like standing more and moving throughout the day, can make a big impact and the recommended "dose" of exercise for heart health. Plus, Dr. Delfiner discusses the number one lifestyle change that can have the greatest impact on your heart health. Resources: American Heart Association's Life's Essential 8 How Stress Affects the Heart + Why You Should Never Shovel Snow If You're Over 45 Years Old Cardiologist Discusses Unassuming Warning Signals From Your Heart, Heart Disease and Preventative Medicine

In this episode, Dr. Luis Taveras, Senior Vice President and CIO at Jefferson Health, shares his insights on leading IT integration after the merger with Lehigh Valley Health Network, transitioning to cloud-based systems, and implementing strategic governance models. He highlights the importance of teamwork, leveraging data as a core asset, and navigating challenges like cybersecurity, financial constraints, and the potential of AI in healthcare.

We're thrilled to announce a major milestone for our organization—our brand refresh! Formerly known as the Pennsylvania Action Coalition, we are now the Pennsylvania Nursing Workforce Coalition, a new name that reflects our mission to place Pennsylvania's nursing workforce at the forefront of healthcare. In this episode, we dive into our vision and strategic priorities as we embark on a five-year plan to advocate, support, and advance a nursing workforce that drives a healthier Pennsylvania. Our approach includes three core initiatives: bolstering nursing workforce pathways, reimagining public policy through data, and embracing diversity with equitable solutions. We'll be joined by Daniel Hudson, Vice President and Associate Chief Nurse Executive for Nursing Operations and Administration at Jefferson Health in Philadelphia. Daniel is one of our newest advisory board members, and he brings invaluable expertise in nursing workforce optimization, care delivery, and staff engagement. We'll be discussing the future of nursing, healthcare trends, and how Daniel's extensive experience can help us move closer to our goals.

In this pivotal episode of "The Engineers HVAC Podcast," join Tony Mormino and Frank Campisino, PE, Senior Mechanical Engineer at Barton Associates, Inc., for a deep dive into the critical HVAC challenges faced in healthcare facilities. This discussion, coordinated by Matt Clark of Engineered Building Systems, features John Ardente, Facilities Operations Manager at Jefferson Health. Together, they explore the practical concerns and safety measures surrounding using A2L refrigerants within Jefferson Health's complex environments. Tune in as these seasoned experts tackle flammability risks, adapt to new refrigerant requirements, and offer invaluable insights for HVAC professionals in the healthcare sector. Credit to Chemours for the A2L refrigerant video shown in this presentation.

As violent crime has trended slightly downward throughout the United States over the last year, a wound to this country's collective psyche that appears reluctant to close is workplace violence in America's hospitals.Reporting the lead story during the next live edition of Monitor Mondays will be special assignment contributor Dennis Jones, senior director of revenue cycle at Jefferson Health.Jones returns to his beat to continue his reporting of this issue. Among those healthcare professionals most at risk for workplace violence are nurses and those who work in emergency rooms. In fact, a 2021 study conducted by the Cleveland Clinic revealed that workplace violence tends to be four times more prevalent in healthcare than in other industries. Jones is expected to have more details on “Violence in America's Hospitals.”Other segments during the weekly Internet broadcast will include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Legislative Update: Cate Brantley, senior government analyst for Zelis, will report on current healthcare legislation.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.

In this episode, infectious diseases expert Dr. John Zurlo returns to the podcast to provide essential updates on the latest COVID-19 booster. As we move into the fall season, Dr. Zurlo shares crucial information about whether you should consider getting the updated COVID booster and how to time your flu shot this year for maximum protection. Dr. Zurlo also offers a reminder on what to do if you test positive for COVID, including common symptoms and treatment options. Plus, he provides an update on long COVID, including what symptoms to look out for and how to best advocate for yourself if you think you might have it. Listen and subscribe to the Living Well Podcast by Jefferson Health on your preferred players: Spotify, Apple Podcasts, Podbean.

Dr. Anish Koka, a cardiologist at Jefferson Health, returns to the show for the first time since the inaugural episode in October 2020. With a sharp focus on healthcare policy, he delves into the impact of the Affordable Care Act on his practice, critiques the influence of political biases in academia, and shares his bold ideas for making healthcare insurance accessible and affordable. Dr. Koka also offers insights on prior authorization alternatives, the Inflation Reduction Act, 340B, and much more in this thought-provoking and, at times, contentious discussion. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Tune in to the latest episode of the Becker's Healthcare Podcast, recorded live at our 14th Annual Meeting, where we delve into insightful discussions with industry experts. Join Dr. Stacey-Ann Okoth, SVP, System Associate Chief Nurse Executive at Jefferson Health, as they share invaluable insights on leadership, growth strategies, and navigating workforce challenges in healthcare. Gain actionable advice and best practices to elevate your organization's performance in today's dynamic landscape.

Jefferson Health and Lehigh Valley Health Network sign an agreement to merge. Preliminary data shows a drop in overdose deaths in 2023. Marking the first decline in years. And Novo Nordisk will test whether its weight-loss drugs can help people with alcohol-related liver disease. That's coming up on today's episode of Gist Healthcare Daily. Hosted on Acast. See acast.com/privacy for more information.